logo
World must ‘start screening for prostate cancer to stop men being left behind'

World must ‘start screening for prostate cancer to stop men being left behind'

Telegraph3 days ago

Every country should have a strategy for tackling prostate cancer with dedicated screening programs for men over 50, a leading health charity has said.
Global Action on Men's Health, the leading international charity for men's health, is calling for prostate cancer – now the third most common cancer worldwide – to be dramatically elevated on the health agenda.
On Monday it will launch a campaign to encourage all countries with adequate resources, including the UK, to launch national screening for the disease in a bid to cut unnecessary deaths.
It will also call for the World Health Organization (WHO) to introduce a Global Prostate Cancer Initiative which 'covers every stage of the prostate cancer pathway from prevention to palliative care'.
Prostate cancer is now the most frequently diagnosed cancer in men in 112 countries and the leading cause of cancer death among men in 48 countries.
In England, it is now the most common cancer, killing some 12,000 men every year, according to Prostate Cancer UK.
Writing in today's Telegraph, Peter Baker, the director of Global Action on Men's Health, said that men were being short-changed when it comes to healthcare.
'Men's health has been neglected for far too long with devastating consequences,' he writes. 'Globally, men's life expectancy lags five years behind women's. Men are significantly more likely to develop and die from cancer, heart disease, diabetes and tuberculosis. They are also at much greater risk of dying from suicide or an accident on the roads or at work.'
Mr Baker calls for reform across health care systems – ensuring men have better access to GPs, for instance – and believes that a focus on prostate cancer is a good place to start.
Rapid advances in screening technologies now mean that developed nations should soon be able to launch screening programs that will cut death rates by a third or more and reduce the dramatic social inequalities associated with the disease.
Men with a family history of prostate cancer run a significantly higher genetic risk of developing prostate cancer, as do black men. Men from lower socioeconomic backgrounds are also much harder hit, due to a combination of poor health literacy and access to healthcare.
The European Commission recently recommended introducing national prostate cancer screening across all 27 member states of the European Union, and already countries including Sweden and Norway have either launched or are on the brink of launching national screening programs.
While blood tests for prostate cancer, known as prostate-specific antigen tests (PSA), have been available for many years, they throw up a large number of false positives.
This in turn led to many unnecessary prostate removals and biopsies being performed, meaning the risks outweighed the benefits of running national screening programmes.
But now, with the advent of more specific blood tests and high resolution MRI scans, which allow for much more accurate biopsies, the balance has changed, with several high quality studies showing the benefit of screening.
The largest of these studies was the European Randomised Study of Screening for Prostate Cancer (ERSPC), which included over 182,000 men and showed a 20 per cent reduction in prostate cancer mortality among those screened.
Another study in Gothenburg, Sweden, found that after 18 years of follow-up, men in the screening group were 35 per cent less likely to die from prostate cancer than men who were not screened. Men who started screening at age 55-59 were 53 per cent less likely to die.
Professor Jonas Hugosson, a urologist at University of Gothenburg in Sweden who led the Swedish study, said he expected national screening for prostate cancer to be rolled out across most western European nations in the next few years.
In Sweden a move to nationwide screening was already progressing and in Norway he expected a national screening program to be announced shortly, he said. However, just as with the roll out of breast cancer screening more than three decades ago, it would take most countries many years to gear up.
'In my view, we have quite a new situation today, and I think it's time for the health authorities to take a new standpoint,' he said.
'I'm quite sure about that and we will see screening come all over Europe during the coming years, but it takes 10 years to build up, at least.'
'Alarming and unacceptable' rise in cases
The NHS in England does not have a dedicated men's health strategy but one has been promised by the end of the year by the new Health Secretary, Wes Streeting.
Although the new strategy is unlikely to include the imminent launch of a national screening program for prostate cancer – the UK currently does not have the MRI machines and trained staff needed to launch one – it may include screening for high risk groups.
These include black men, who have double the normal risk, and men with a family history of prostate and related cancers – including breast and ovarian cancer on the female side.
In October last year, six-time Olympic cycling champion Sir Chris Hoy, 49, revealed that he had terminal prostate cancer. Both his father and grandfather had the disease but his was not caught by early testing, sparking an outcry.
'The rapid rise in prostate cancer cases is not just alarming, it is also unnecessary and therefore unacceptable,' said Global Action on Men's Health. 'Prostate cancer is currently inadequately addressed in global and national cancer policies'.
In addition to national testing where possible, the charity is calling for the WHO to support a new Global Prostate Cancer Initiative covering 10 areas.
These include governments being urged to introduce national cancer plans which specifically address prostate cancer with clear performance indicators, education programmes to raise awareness and tackle stigma, and investments in research, infrastructure, workforce development and treatments for prostate cancer.
The WHO does not currently have a programme that focuses specifically on prostate cancer but 'integrates' it to its wider program for tackling cancer more generally.
Cervical cancer, in contrast, has a dedicated programme dedicated to its global eradication but that is because the HPV vaccine makes it possible to wipe out the disease completely.
Dr André Ilbawi, technical lead for cancer control at the WHO, welcomed the prostate campaign launched by Global Action on Men's Health, and said the disease was moving up the WHO's agenda.
The organisation had just five countries involved in its cancer programme in 2015 to but has 100 today.
'We see prostate cancer as a priority and, in 2023, elevated it in our guidance because it can be treated,' said Dr IIbawi.
'If treatment is available, survival is extremely high. And if treatments are not available, those men will die.
'We agree that prostate cancer should be seen in the cancer agenda as high impact, cost-effective and meeting community needs'.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Reeves announces £6 billion to provide millions of NHS tests and procedures
Reeves announces £6 billion to provide millions of NHS tests and procedures

The Independent

time30 minutes ago

  • The Independent

Reeves announces £6 billion to provide millions of NHS tests and procedures

Rachel Reeves has announced a £6 billion investment to speed up tests and treatment within the NHS, after setting out huge year-on-year rises in the health service's budget. New scanners, ambulances and urgent treatment centres are among the things which the additional cash will pay for, with the aim of providing up to four million more tests and procedures over the next five years. The announcement comes after the Chancellor put NHS funding at the heart of her spending review on Wednesday, raising its budget in a move worth £29 billion a year. This comes, however, at the expense of other areas of public spending. The new £6 billion funding will help to meet the Government's target of reducing NHS waiting lists in England, the Chancellor claimed. 'Over a decade of underinvestment from the previous government put the NHS on its knees, with people across the country unable to get the care they need. We are investing in Britain's renewal, and we will turn that around,' Ms Reeves said. She added: 'Part of our record investment will deliver four million tests, scans and procedures, so hard-working people can get the healthcare they and their families need. 'There is no strong economy without a strong NHS, and we'll deliver on our Plan for Change to end the hospital backlog, improve living standards and get more money in people's pockets.' The latest spending commitment will help patients get access to diagnostic scans and treatment in places such as shopping centres and high streets, speeding up their diagnoses. The Government hopes this will help to cut NHS waiting lists, meeting Labour's goal of ensuring the health service carries out 92% of routine operations within 18 weeks. Health Secretary Wes Streeting said: 'Since taking office we have been relentless in our drive to cut waiting times for patients, delivering over 3.6 million extra elective care appointments and reducing the overall waiting list by over 200,000. 'The £6 billion investment we are announcing today will generate millions more vital diagnostic tests, scans and procedures for patients across the country.' On Wednesday evening, Ms Reeves said the Government was 'confident' it could meet its pledge to reduce waiting lists after giving the NHS a 3% annual increase in funding at the spending review. Some health leaders are, however, sceptical that the Government will meet its target, despite the funding boost provided at the spending review. Matthew Taylor, chief executive of the NHS Confederation, which represents all health organisations, warned 'difficult decisions will still need to be made as this additional £29 billion won't be enough to cover the increasing cost of new treatments, with staff pay likely to account for a large proportion of it'. He added: 'So, on its own, this won't guarantee that waiting time targets are met.' Sarah Woolnough, chief executive of the King's Fund charity, said: 'The Chancellor said she wants the public to have an NHS there when they need it. 'It is hard to see how all the things she mentions: faster ambulance times, more GP appointments, and adequate mental health services and more can be met on this settlement alone. 'Particularly when large parts of this additional funding will be absorbed by existing rising costs, such as the higher cost of medicines, which are currently being negotiated, and covering staff pay deals.'

NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms
NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms

The Independent

timean hour ago

  • The Independent

NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms

Rachel Reeves has pledged a £6bn investment aimed at accelerating tests and treatments within the NHS, following substantial year-on-year budget increases for the health service. The additional funding will facilitate new scanners, ambulances, and urgent treatment centres, with the goal of delivering up to four million more tests and procedures over the next five years. This announcement follows the chancellor's emphasis on NHS funding in her recent spending review, where she allocated an additional £29bn annually to the NHS budget. However, this increase comes at the expense of other areas of public spending. The £6bn boost is intended to support the Government's objective of reducing NHS waiting lists in England, according to the chancellor. 'Over a decade of underinvestment from the previous government put the NHS on its knees, with people across the country unable to get the care they need. We are investing in Britain's renewal, and we will turn that around,' Ms Reeves said. She added: 'Part of our record investment will deliver four million tests, scans and procedures, so hard-working people can get the healthcare they and their families need. 'There is no strong economy without a strong NHS, and we'll deliver on our Plan for Change to end the hospital backlog, improve living standards and get more money in people's pockets.' The latest spending commitment will help patients get access to diagnostic scans and treatment in places such as shopping centres and high streets, speeding up their diagnoses. The Government hopes this will help to cut NHS waiting lists, meeting Labour's goal of ensuring the health service carries out 92 per cent of routine operations within 18 weeks. Health Secretary Wes Streeting said: 'Since taking office we have been relentless in our drive to cut waiting times for patients, delivering over 3.6 million extra elective care appointments and reducing the overall waiting list by over 200,000. 'The £6bn investment we are announcing today will generate millions more vital diagnostic tests, scans and procedures for patients across the country.' On Wednesday evening, Ms Reeves said the Government was 'confident' it could meet its pledge to reduce waiting lists after giving the NHS a 3 per cent annual increase in funding at the spending review. Some health leaders are, however, sceptical that the Government will meet its target, despite the funding boost provided at the spending review. Matthew Taylor, chief executive of the NHS Confederation, which represents all health organisations, warned 'difficult decisions will still need to be made as this additional £29bn won't be enough to cover the increasing cost of new treatments, with staff pay likely to account for a large proportion of it'. He added: 'So, on its own, this won't guarantee that waiting time targets are met.' Sarah Woolnough, chief executive of the King's Fund charity, said: 'The chancellor said she wants the public to have an NHS there when they need it. 'It is hard to see how all the things she mentions: faster ambulance times, more GP appointments, and adequate mental health services and more can be met on this settlement alone. 'Particularly when large parts of this additional funding will be absorbed by existing rising costs, such as the higher cost of medicines, which are currently being negotiated, and covering staff pay deals.'

UK Pharmaceutical industry at risk from government's 'sky-high' rebates system
UK Pharmaceutical industry at risk from government's 'sky-high' rebates system

Daily Mail​

time2 hours ago

  • Daily Mail​

UK Pharmaceutical industry at risk from government's 'sky-high' rebates system

The UK's status as a leader in medical research is at risk from 'sky-high and unpredictable' repayments pharmaceutical firms hand the Government, says an industry boss. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said the rebate system – where firms repay money they make through selling medicines to the NHS – was sending 'a terrible message to international investors'. Rachel Reeves promised to support 'the UK's strengths in life sciences' and 'ensure patients get rapid access to the most clinically and cost-effective new technologies'. The Treasury plans to invest up to £520million in drug manufacturing in the next five years. Another £600million is earmarked for a health data research service to accelerate the discovery of new medicines. But Torbett said more was needed. 'Over the past decade, accounting for inflation, the NHS budget has grown by a third in real terms, while investment in the most rigorously cost-benefit-tested part of health spending – investment in the medicines needed to treat people – has fallen from around 11 per cent to 9 per cent of the health budget,' he added. And he attacked plans to increase what drug companies must repay from drug sales to 31.3 per cent, from 15.5 per cent. 'The sky-high and unpredictable payment rates send a terrible message to international investors when the UK is trying to position life sciences research and development as an engine for health and growth. For the sake of patients, the NHS and the economy, we need a commitment to bring these unsustainable rates down.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store